GeriQBank · Paper IV · Q15
Preliminary Assessment of an Older Male with Lower Urinary Tract Symptoms, and When to Refer to a Urologist
- Chapter
- Endocrine, Metabolic, Renal & Genitourinary Systems
- Years asked
- Not recorded in the source
- Frequency
- Set 1× in Paper IV (2009–2025)
As set in the university paper
What is the preliminary assessment done in an older male with lower urinary tract symptoms? When would you refer to a urologist?
Paper IV · Renal, Genitourinary, Continence & Men's Health · asked ×1 · 7-mark note · see in paper list
Detailed answer
Pro · free in betaAttempt it firstOutline your answer as a 7-mark note before revealing it — definition, causes, evaluation, management and the geriatric angle.Reveal answer
A. Background
Benign prostatic hyperplasia is inexorably linked with ageing and is a major contributing factor in the development of lower urinary tract symptoms (LUTS); the prevalence of BPH-related symptoms may be as high as 50% in multinational surveys.
LUTS are not synonymous with BPH — they may arise from the bladder (overactivity or underactivity), prostate, urethra, or from systemic disease and drugs.
Voiding (obstructive) symptoms: hesitancy, weak stream, straining, intermittency, terminal dribbling, incomplete emptying. Storage (irritative) symptoms: frequency, urgency, nocturia, urgency incontinence. Post-micturition: post-void dribbling.
B. History
Use the International Prostate Symptom Score (IPSS) / AUA Symptom Index — seven items scored 0–5: 0–7 mild, 8–19 moderate, 20–35 severe — plus the disease-specific quality-of-life (“bother”) question.
The score quantifies symptoms over time; bother and quality of life, not the score alone, drive treatment decisions.
A 3-day frequency-volume chart (bladder diary) distinguishes polyuria, nocturnal polyuria and reduced functional bladder capacity — critical in the older man with nocturia.
Exclude other causes by history: type 2 diabetes (nocturia with polyuria >3 litres), neurological disease (neurogenic bladder), gross haematuria or bladder pain (tumour or calculi), urethral trauma, urethritis or instrumentation (stricture), family history of BPH or prostate cancer, and sexual dysfunction-related LUTS.
Drug history is essential — anticholinergics impair bladder function, sympathomimetics increase outflow resistance, diuretics increase frequency, opioids cause retention, and calcium-channel blockers worsen emptying.
Assess fluid, caffeine and alcohol intake, and evening fluid timing.
C. Examination
Digital rectal examination to assess prostate size and consistency and to detect nodules or induration suggesting carcinoma; also assess rectal sphincter tone, and exclude faecal impaction.
Abdominal examination for a palpable bladder (chronic retention), and examination of the external genitalia for meatal stenosis and phimosis.
Focused neurological examination, including perineal sensation and sacral reflexes.
A general health and cognitive status evaluation is useful for choosing the best treatment, especially if a surgical procedure may be required — frailty, cognition and life expectancy determine what is appropriate. Dementia and other neurological conditions can themselves affect the urinary condition.
D. Investigations
Urinalysis in all patients, to detect infection and haematuria; urine cytology is helpful when irritative symptoms or haematuria predominate, especially in smokers, to exclude bladder tumour.
Serum creatinine is not routinely indicated in the initial evaluation of LUTS attributable to BPH, since baseline renal impairment is no commoner in men with BPH than in age-matched peers — but measure it if there is chronic retention, hydronephrosis, or suspicion of obstructive nephropathy.
PSA remains controversial but is still recommended after counselling, and is chiefly appropriate where life expectancy exceeds 10 years and a diagnosis of cancer would change management. Remember: PSA is not cancer-specific and rises in BPH, prostatitis, instrumentation and retention, and about 25% of men with prostate cancer have a PSA of 4.0 ng/mL or less.
Post-void residual urine by bladder ultrasound and uroflowmetry are optional but useful; a poor maximum flow rate, high post-void residual and greater symptom severity predict clinical progression.
Do not perform routine upper-tract imaging, cystoscopy or urodynamics at the preliminary assessment.
E. When to Refer to a Urologist
Refer urgently for: visible (gross) haematuria or persistent microscopic haematuria without infection; abnormal DRE (nodule or induration) or unexplained PSA elevation; and suspected malignancy.
Refer for: acute or chronic urinary retention with a palpable bladder, renal impairment or hydronephrosis attributable to obstruction, bladder or urethral stones, suspected urethral stricture (previous trauma, urethritis or instrumentation), and recurrent urinary tract infection or persistent sterile pyuria.
Refer for: failure of adequate medical therapy, severe bothersome symptoms in a man fit for and wishing to consider intervention, suspected neurogenic bladder, and any patient in whom surgery is being contemplated (complex urodynamic testing is essential before surgical intervention and to define the cause of retention).
Manage in primary care / general geriatric clinic: mild symptoms (IPSS <7) with watchful waiting and lifestyle measures — fluid restriction before bedtime, avoiding caffeine and spicy food, monitoring diuretics, timed voiding and bladder retraining, pelvic floor exercises, and treating constipation. Patients with mild symptoms but severe bother should undergo further assessment.
Latest Updates (2023–Present)
The AUA LUTS/BPH Guideline (2023 amendment, expanded into a three-part guideline in 2026) is the current reference. Initial workup remains history, AUA-SI/IPSS and urinalysis, with explicit elicitation of patient goals and discussion of side-effects.
A major new emphasis is pre-operative assessment of prostate size and shape (ultrasound, cystoscopy or existing cross-sectional imaging) because modality selection now depends on volume — for example, water vapour thermal therapy is offered where prostate volume is under 80 g, with counselling on retreatment rates. Minimally invasive surgical therapies (MIST) — prostatic urethral lift, water vapour thermal therapy, Aquablation, prostatic artery embolisation, temporary implantable nitinol device — are now firmly in the guideline and are particularly attractive in older, frailer men and those wishing to preserve ejaculatory function. Enucleation techniques (HoLEP, ThuLEP) are size-independent options for very large glands. Guidelines now explicitly require counselling about sexual side-effects of medical and surgical therapy, following evidence of poor pre-treatment counselling in practice.
Deprescribing is part of the assessment: reviewing anticholinergics, opioids, diuretics and sympathomimetics frequently improves symptoms without any new prescription.
Nocturia is increasingly managed as a distinct multifactorial syndrome — sleep apnoea, heart failure, oedema, diabetes, drugs and nocturnal polyuria — rather than as a prostate symptom; desmopressin carries a significant hyponatraemia risk in the elderly and requires sodium monitoring.
PSA screening: contemporary guidance supports shared decision-making in men with >10 years’ life expectancy and generally against PSA testing above age 70 or in significant frailty, aligning with geriatric principles of avoiding diagnoses that cannot benefit the patient.
Current Practice Update
Aspect Textbook Position Current Evidence / Guideline Core initial workup History, IPSS, examination, urinalysis Unchanged, plus explicit elicitation of patient goals Prostate size assessment Not routine at first visit Recommended before procedural therapy — determines modality choice Treatment options Watchful waiting, drugs, MIST, surgery Greatly expanded MIST menu; enucleation for large glands Sexual side-effects Mentioned Mandatory counselling in guideline statements Nocturia Part of the symptom score Managed as a separate multifactorial syndrome PSA Recommended with counselling Shared decision-making; generally avoided above 70 or in frailty Exam One-Liners IPSS: 0–7 mild, 8–19 moderate, 20–35 severe — plus the bother question.
A 3-day bladder diary distinguishes nocturnal polyuria from a prostate problem.
Urinalysis in everyone; creatinine not routine; PSA only after counselling.
Red flags for referral: haematuria, abnormal DRE, retention, renal impairment, stones, stricture, recurrent UTI, failed medical therapy.
25% of prostate cancers have a PSA ≤4.0 ng/mL.
Review the drug chart before writing a new prescription.
How was your recall?
Rating marks the question complete. “Need another pass” also adds it to your bookmarks.
References
- PAPERS-2-3-4_COMBINED.pdf — page 1208
- GeriQBank source PDF — p. 1208
Spotted an error or something out of date?Report a problem with this page